Novo Nordisk Launches Oral Ozempic for Type 2 Diabetes in U.S.

Novo Nordisk (NYSE: NVO) is launching an oral version of Ozempic for adults with type 2 diabetes in the U.S. starting May 4, 2026. The FDA-approved medication marks the first oral peptide GLP-1 approved both to lower blood sugar and reduce major cardiovascular events in adults at high cardiovascular risk.

Dosing and Pricing

Ozempic tablets are available in 1.5mg, 4mg, and 9mg doses through over 70,000 pharmacies nationwide. Patients with insurance may access the medication for as little as $25 for up to three months, while out-of-pocket costs range from $149 to $299 monthly depending on dose. The medication will be produced entirely in the U.S. and offered through NovoCare Pharmacy and select telehealth providers.

Rebranding Strategy

The oral pill contains reformulated semaglutide strengths previously sold as Rybelsus in 3mg, 7mg, and 14mg tablets. The rebranding simplifies treatment choices for healthcare professionals and patients, many of whom were unaware that an oral semaglutide option has existed since 2019.

Cardiovascular and Future Approvals

The medication is approved to reduce risk of heart attack, stroke, or death in adults with type 2 diabetes at high cardiovascular risk. In adults with chronic kidney disease, it helps control blood sugar and reduce cardiovascular and kidney-related complications. Novo Nordisk has filed for FDA approval of a 25mg tablet, with a decision expected by year-end 2026.